GeoVax Announces Allowance of Patent Protecting Multi-Antigen COVID-19 Vaccine Constructs

About this update from Geovax Labs, Inc.

[{"type":"image","caption":"","headline":"GeoVax Labs Announces $1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules","size":{"original":{"width":140,"height":140,"url":"https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/CK3y_RQaAtNDQGf8lPQXOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/newsmediawire_165/6b870301b9c37c9b2d12fc8f9b2a2ecc","width":140,"height":140}}},{"type":"text","content":"Expands Intellectual Property Portfolio Supporting Next-Generation COVID-19 Vaccine Candidates ","length":94,"tagName":"p"},{"type":"text","content":"ATLANTA, GA - August 20, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/888,131, titled "Vaccines and Uses Thereof to Induce an Immune Response to SARS-CoV-2."","length":417,"tagName":"p"},{"type":"text","content":"The allowed claims broadly cover recombinant Modified Vaccinia Ankara (MVA) viral vectors encoding multiple SARS-CoV-2 proteins - including Spike (S), Membrane (M), and Envelope (E) antigens - configured to generate virus-like particles (VLPs) upon expression. These constructs are designed to induce both antibody and T-cell responses, providing durable and broad immune protection against current and emerging variants of SARS-CoV-2.","length":435,"tagName":"p"},{"type":"text","content":"Key features of the allowed claims include:","length":43,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Multi-antigen design (Spike, Membrane, and Envelope proteins) to mimic the natural virus structure and induce robust immune responses.","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"VLP formation within host cells, enabling presentation of antigens in their natural conformation for optimal immune recognition.","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"Coverage of both ancestral strain sequences and variant-associated mutations (e.g., K417N/T, E484K, N501Y) to address immune escape.","length":132,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":394,"olType":fal...

More updates from Geovax Labs, Inc.